Topical tropomysin kinase (TRK) inhibitor as a treatment for inherited CYLD-defective skin tumours (TRAC)

Trial Profile

Topical tropomysin kinase (TRK) inhibitor as a treatment for inherited CYLD-defective skin tumours (TRAC)

Completed
Phase of Trial: Phase I/II

Latest Information Update: 27 Jun 2018

At a glance

  • Drugs Pegcantratinib (Primary)
  • Indications Skin tumours
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms TRAC
  • Most Recent Events

    • 27 Jun 2018 Results published in the JAMA Dermatology
    • 03 Apr 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top